The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices go down. When compared to a stock’s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the RSI is below 30, according to Benzinga Pro.
Here’s the latest list of major oversold players in this sector, having an RSI near or below 30.
Viking Therapeutics Inc VKTX
- On Jan. 17, HC Wainwright & Co. analyst Joseph Pantginis reiterated Viking Therapeutics with a Buy and maintained a $102 price target.. The company’ stock fell around 22% over the past month and has a 52-week low of $20.83.
- RSI Value: 28.8
- VKTX Price Action: Shares of Viking Therapeutics gained 0.7% to close at $32.87 on Tuesday.
- Benzinga Pro’s real-time newsfeed alerted to latest VKTX news.
Radnet Inc RDNT
- On Jan. 15, Jefferies analyst Brian Tanquilut maintained RadNet with a Buy rating and lowered the price target from $100 to $80. The company’s stock fell around 11% over the past five days and has a 52-week low of $35.16.
- RSI Value: 25.2
- RDNT Price Action: Shares of Radnet gained 0.6% to close at $60.19 on Tuesday.
- Benzinga Pro’s charting tool helped identify the trend in RDNT stock.
Vera Therapeutics Inc VERA
- On Jan. 13, Vera Therapeutics secured an exclusive license from Stanford University for VT-109, a next-generation fusion protein targeting BAFF and APRIL. VT-109 offers broad therapeutic potential for B cell-mediated diseases, reinforcing Vera’s position in B cell modulation. The company’s stock fell around 20% over the past month and has a 52-week low of $15.46.
- RSI Value: 27.2
- VERA Price Action: Shares of Vera Therapeutics gained 1% to close at $33.70 on Tuesday.
- Benzinga Pro’s signals feature notified of a potential breakout in VERA shares.
Read This Next:
Market News and Data brought to you by Benzinga APIs
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.